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Abstract
Atherosclerosis is the underlying factor leading to such cardiovascular
diseases (CVD) as stroke, aneurysm, and myocardial infarction. The early detection
of atherosclerotic plaques is considered to be crucial for successful prevention
andlor therapeutic and dietary intervention of CVD. Current diagnostic practice. on
the other hand. can only detect the problem at an advanced stage. The purpose of
the work in this thesis was to examine the potential of using non-hydrolyzable
radioimaging agents facetylated low density lipoprotein (AcLDL) conjugates as
diagnostic drugs for the early and non-invasive detection of atherosclerosis and for
the monitoring of the effects of drug therapy.
Cholesteryl iopanoate (CI), a cholesteryl esteranalog, 1.3-dihydroxypropan-2-
one 1.3-diiopanoate (DPIPj, a diglyceride analog, and a newcompound, cholesteryl
1,3-diiopanoate glyceryl ether (C21), were synthesized, radiolabeled, and
incorporated into AcLDL to use as radiotracers for testing their potential dinical use
in the early diagnosis of atherosclerosis in experimental rabbits. Biodistribution of
these agents was studied, and aortae of both atherosclerotic lesioned and control
rabbits were removed for Sudan IV staining and autoradiography in orderto confirm
the fonnation of the atherosclerotic lesion and localization of radioactivity
respectively.
The injected drugs were found to be cleared from blood following a two
compartment model. All of the three drugs were shown to be resistant to hydrolysis
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in vivo. Radioactivity in the atherosclerotic aorta was found to be significantly higher
than that in normal aorta in terms of CI and C21 compounds, suggesting that both of
the proposed diagnostic probes were selectively taken up by the atherosclerotic
lesions. The autoradiography and staining results confirmed that the localization of
the proposed probes was superimposed with the atherosclerotic lesion site. Work
in this regard was published in part (Xiao et at, 1999a) and summarized in Chapter
2.
Other work included in this thesis contains a method we developed in our lab
to significantly enhance the drug loading efficiency into lDl using a microemulsion
with seal oil as the major constituent (see Xiao et aI., 1999b and Chapter 3 for
details), and the research on the potential of using DPIP loaded LOL as a tumor
imaging agent for the detection of cervical tumors (see Xiao et at, 1999c and
Chapter 4 for details).
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Chapter 1. Introduction
Atherosclerosis is a long·term. progressive disease of blood vessels with
cellular and metabolic alterations, including cellular proliferation and accumulation
of low-<lensity lipoproteins (LDL) in the mural arteries (Ross, 1993). In most cases
of atherosclerosis the elastic arteries (aorta, carotid and iliac) and some of the large-
and medium-sized muscular arteries (coronary and popliteal) are pathologically
changed. The coronary arteries, the popliteal arteries, the descending thoracic
aorta, the intemat carotid arte,"",lS and the velS:sellS of e1n::1e of wtllllS lite lSome of the
most severely invotved vessels. More specifICally, coronary carotid, cerebral arteries
and the aorta are the prime foci of atherosclerotic complications, and as a result,
thrombotic myocardial infarction, thromboembolic cerebral infarction and aortic
aneurysms are the major consequences of this disease.
It takes decades to develop the mature atherosclerotic plaques thatwill cause
the clinical complications, such as thrombotic and thromboembolic occlusion and
aneurysms. Atherosclerosis is the leading cause of lTIOrt>idity and mortality in the
Western work!, and nearty 50% of all deaths in the U.S. are generally attributed to
diseases associated with atherosclerosis. Therefore, quantitative assessment of
atherosclerotic oratherothromboticdisease during its evolution and after therapeutic
inteNentions is important fOf understanding the progression of the disease and for
selecting appropriate medicinal or surgical measures.
Many invasive and noninvasive imaging techniques have been available for
-1-
detecting characteristics of vascular lesions. Before introducing these detection
methods, some description of atherosclerotic plaque composition and morphology
would be helpful.
Composition and Morphology of the Plaque
Typically the mature atherosclerotic plaques consist of the Iipid·rich
atheromatous gruel and collagen·rich sclerotic tissue (Falk et at, 1995). The basic
lesion appears white or whitish yellow and consists of a raised focal plaque which
contains a lipid core and a covering fibrous cap within the intima. The core within the
plaque contains crystalline cholesterol, cholesteryl esters, phospholipids, cellular
degradation products and collagen remnants (Stary et al., 1994: Stary et al., 1995).
The fibrous cap covering the core is composed of smooth muscle celts,
macrophages and collagen oontents. As the plaque grows, the lumen of the artery
is encroached with stenosis. The morphological features of atherosclerotic lesions
are characterized by lesion length, smoothness of lumen outline, eccentricity of the
lumen, abrupt or tapered shoulders, defects due to thrombus, and the presence of
calcification. Current knowledge about the pathophysiology and progression of
atherosclerosis has suggested that the composition and vulnerability to pathology
of the plaque is related to the clinical status of the patient. and the sudden
conversion of a stable atherosclerotic plaque to an unstable and life-threatening
atherosclerotic lesion or vulnerable plaque is caused by plaque fiSSUring. rupture or
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disruption (Falk and Femandez-Qrtlz, 1995; Maximilian and WiUerson, 1994:
Kaartnen et at, 1994).
According to the criteria set forth by the American Heart Association
Committee on Vascular lesions, plaque progression in coronary arteries can be
subdivided into five phases and various lesion types, as shown in Figure 1 (Stary et
at, 1994: Stary et at, 1995). Phase 1 lesions can usually be found in people
younger than 30. Such small lesions may progress over a period of years and are
categorized as type I, 11 and III lesions. Phase 2 indicates plaques that. although not
necessarily stenotic, may be prone to disruption because of high lipid content. The
lesions are categorized as type IV or Va. Phase 2 can proceed into acute phase 3
or 4. and both of these can evolve into fibrotic phase 5. Phase 3 consists of the
acute type VI lesions with a mural thrombus that could possibly occlude the artery.
Phase 4 oonsists afthe acute complicated type VI lesion with an occlusive thrombus.
which may result in an acute coronary syndrome.
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Figure 1. ClassifICation of coronary atherosclerotic lesions in terms of their phases,
morphology and histopathology.
lesion lesion
Type Morphology
Clinical
Symptoms
Phase 1
Phase 2
Phase 3
Phase 4
Phase 5
Foam cells
Foam cells, smooth muscle cells
and extracellular lipid droplets No symptoms
III Smooth muscle cells surrounded
by extracellular connective tissue.
fibrils and lipid deposits
IV Confluent cellular lesions wllh a
great deal of extracellular lipid.
intermixed with fibrous connective
tissue
Va ElClracellular lipid covered by thin
fibrous cap
VI Disruption of type IV and Va
lesions with a mural thrombus
that mayor may nol occlude the
arte'Y
VI Disruption of type IV or Va lesions Acute syndromes.
with occlusive thrombus myocardial
Infarction,unstable
angina, ischemic
sudden death
Vb-Vc Changes in geometry of the Silentocctuslve
disrupted plaque. and process or Angina
organization of mural thrombus by pectoris
connective tissue may lead to
formation of occlusive and fibrotic
type of lesions
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In Phase 5, changes in the shape of disrupted plaques and the organization
of connective tissues can lead to the more occlusive and fibrotic type Vb or Vc
lesions. These occlusive lesions can be clinically silent or produce angina.
Coronary occlusion and myocardial infarction are most frequently developed
from mild-ta-moderate stenosis of lipid-rictllesions. It has been observed that acute
ischemic events are due to the disruption of lipid·rich lesion types IV and Va, which
...e often invisible to angiography. Therefore, the imaging of less obstructive lipid-
rich plaques vulnerable to rupture would be valuable for dinical interventions. While
they are in carotid arteries. the vulnerable plaques are severely stenotic and appear
to be ulcerated and disrupted. Once the fibrous cap in lipid-rich ooronary plaques
disintergrates. tears or breaks and exposes the thrombogenic gruel to the flowing
blood, a type IV or Va lesion suddenly evolves into an acute complicated type VI
lesion (Falk and Femandez-Qrtiz, 1995). In contrast, the vulnerable carotid plaques
are heterogeneous and stenotic. Their rupture or dissection probably relates to the
impact of blood flow.
Plaques containing large and soft cores of liquid cholesterol esters are highly
vulnerable to rupture and thrombosis (Falk and Fernandez-Ortiz, 1995). On the
contrary. hard sclerotic plaques with a high oontent of smooth musde cells and
collagen are less susceptible for rupture. Fibrous caps vary widely in thickness,
cellularity, matrix, strength and stiffness. The thinnest parts of them are usually at
their shoulder regions, where macrophages accumulate and disruption often occurs
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(Moreno et at., 1994). In vitro studies suggest that infiltration of macrophage and
their release of metalloproteinases weakens the caps locally (Galis et al., 1995).
Imaging Devices for Atherosclerosis
Several invasive and noninvasive devices or instruments are routinely used
to identify atherosclerosis and to assess the progression of the disease. Most of the
standard techniques measure the morphological parameters of the atherosclerosis,
including the decrease of the luminal diameter or stenosis and the increase of the
wall thickness, and provide qualitative orsemiquantitative assessment of the relative
risk associated with the disease. These techniques will be described in the following
context
Angiography is used to reveal the luminal diameter and provide a measure
of stenosis with excellent resolution, but not to image the vessel wall and its various
histopathological oomponents. This technique is most widely employed for the
diagnosis ofcoronary (Galis et aI., 1995; Ambrose, 1996), carotid (Kohler, 1996) and
peripheral artery (DinslTK>re and Rivitz. 1996) lesions, and is the "gold standard" for
anatomic diagnosis despite limited specificity and sensitivity.
Angioscopy is a method for the visualization of the arterial wall rather than
lumen. It reveals the plaque and surface features that are not seen angiographically
(Den Heijeretal., 1994; Uchida etal.. 1995). In addition, it is able to show the oolor
of the materials in the artery, and it therefore is highly sensitive for the detection of
-<l-
thrombus. However, since it views only the lesion surface, it cannot present the
internal heterogeneity of the plaque. As a routine clinical tool, it may not be practical
due to the thickness of the catheter.
Catheter·based ultrasound is a new approach to the imaging of vascular
anatomy. This technique permits direct imaging of atheroma and provides a cross-
sectional, tomographic perspective of the vessel and the atherosclerotic disease
(Nissen et al.. 1996; Von Birgelen et al., 1995; Roelandt et at. 1994). The diagnostic
applications of intravascular ultrasound include the detection of angiographically
unrecognized disease, detection of lesions ofuncertain severity (40%-75% stenosis)
and risk stratification of atherosclerotic lesions in interventional practice.
A major cause of ischemic cerebrovascular disease is extracranial carotid
atherosclerosis, because stroke and transient ischemic attacks are commonly
associated with advanced atherosclerosis at the carotid bifurcation (Kohler, 1996).
Duplex imaging (B-mode Ultrasound) is typically used to detect extracranical carotid
atherosclerosis due to its noninvasiveness. Clinically. it has been used to evaluate
the efficacy of drugs and study the natural history of atherosclerosis (longitudinal
studies) by follow-up individuals at increased risk of atherosclerosis (Eliasziw et at,
1995).
Calcification of atherosclerotic lesions is an organized and regulated process
and is found more frequently in advanced plaques (Wexier et aI., 1996). A dear
association between coronary calcium and obstructive coronary artery disease has
been established. and it was dearly shown that the amount of coronary calcium was
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a useful indicator of the extent of coronary artery disease (Agatston et at. 1990).
Electron beam computer tomography (EBCT), magnetic resonance imaging (MRI),
fluoroscopy, and helical CT are frequently used to identify calcifIC deposits in blood
vessels, of which, however, only EBCT can quantitate the amount or volume of
calcium (Wexler et aI., 1996). EBCT detects the presence and progression of
atherosclerotic lesions in the prlH:Omplicated stage by monitoring the presence of
coronary artery calcium (Janowitz et aI., 1993).
Similar to conventional angiography techniques, magnetic resonance
techniques use gradient echo methods to generate images of flowing blood as
positive contrast within the lumen of the vessel (Doyle and Pohost, 1996; Grist and
Turski, 1996). Magnetic resonance angiography (MRA) of coronary arteries is
currently under development, and the resolution is in the range of 1 mm3• MRA
techniques provide images of the vessel lumen, whereas MRI aims at evaluating the
effects of the disease on the tissue supplied by the vesse!. It has been reported that
MRI techniques are valuable for studying the progression of experimental
atherosclerosis in hypercholesterolemic rabbits and for imaging the plaque
components such as fibrous caps, necrotic cores and intraplaque hemonhage
(Skinner et al., 1995).
Based on the above summary of the non·radioactive imaging techniques, the
traditional -gold standard-, angiography, detects advanced lesions and provides a
measure of the degree of stenosis. Angioscopy, on the other hand, clearly identifieS
the presence of thrombus. These techniques, however, are ineffective in
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determining which plaques are unstable and vulnerable to thrombosis and
proliferation. In carotid arteries and arteries in lower extremities, duplex
ultrasonography is useful for providing the degree of stenosis as well as plaque
morphology, and for assessing changes in wall thickness. Although appearing to be
the only clinically useful technique in imaging the unstable, vulnerable plaques in
coronary arteries, intravascularultrasound however isvery invasive, like angiography
and angioscopy, and is, therefore, not practical in evaluating the progression of
atherosclerotic disease in patients with stable angina. MRA, being noninvasive, may
replace angiography for anatomical imaging of the vasculature, but the MRA
technique is also ineffective in imaging the vulnerable plaques. In the near future,
magnetic resonance imaging techniques may be able to image vulnerable plaques
and characterize plaques in terms of lipid and fibrous content and identify the
presence of thrombus associated with the plaques. Ultrafast EBCT is noninvasive
and useful for measuring the calcium content in the coronary arteries, but a good
correlation between calcium concentration and plaque vulnerability has not been
confirmed in dinics. Considering aU the imaging devices used to detect the plaques
at relatively advanced phases, radioimaging of the atherosclerosis at its early stages
in which no symptom is dinically shown provides us a new noninvasive approach to
the visualization of the lesions for identification and treatment purposes.
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Radiotracers and Radlolmaglng of Atherosclerosis
The principal mechanisms involved in human atherogenesis are lipid
infiltration, cellular invasion and proliferation and thrombus formation. In the last 20
years, various radiotracers have been developed based on several molecules and
cells involved in atherogenesis, and the potential diagnostic utility of these
radiotracers for imaging atherosclerotic lesions has been studied by many
investigators in animal models (Sinzinger and Virgolini, 1990; Kritz et at, 1996;
Strauss, 1996). These radiotracers are categorized into seven classes (Table I) and
will be described in detail as follows.
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Table l. Radiotracers for imaging atherosclerosis
Ca!eoodes Qf radjQtracers
Immunogloblins
Nonspecific
Specific monoclonal
i Spedfic
~
z
Low Density Lipoprotein (LOL)
Peptides
Monocytes
Metabolic tracer
Photosensitizer
Endogenous Lipid Analogs
Radjotracers
l11In·DTPA_human polyclonallgG (may
bind to Fc receptors on macrophages)
11lIn-(DTPA-PL)-Z2D3 F(ab'h IgM
(antibody against smooth muscle cells)
1311_anti_ICAM_1 monoclonal IgG
(antibody against endothelial adhesion
molecule)
12$1_ or 131 1. or 1231-LOL, l11In_LOL. ~c­
LDL and oo.n-rc-ox-LDL
1231·SP-4, --rc-P199 and -"c-P215
(peptides based on apo B-1OO)
l11ln_monocytes
1SF.fluorodeoxygluoose (FOG) (may
reflect macrophage density)
Benzoporphyrin derivative (BPO)
monoacid ring A
12$I-cholestery lopanoate C2:5I-CI), 1251.
~ .3~i~~~:a~~ (r~_~~~p),n ;~d O,~~
cholesteryl 1.3-diiopanoate glyceryl
etber C:Z=;I.C2!l
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Foam cells derived from macrophages are found in great amount in the fatty
streaks and vulnerable plaques. It has been hypothesized that radiolabeled
immunoglobulin, IgG, would be an appropriate radiolracer to image the Fc receptors
on these cells in the atherosderotic areas (Fischman et aI., 1989). In patients with
carotid atherosclerosis. l11ln_labeled IgG identified 86% of the lesions determined by
ultrasonography. However. it did not correlate with plaque morphology and clinical
stage of the disease. as determined by ultrasound (Sinzinger et at, 1996). Failure
of detecting the eal1y lesions in the aorta of Watanabe heritable hypel1ipidemic
rabbits using 1111n_lgG was reported, possibly because of the slow plasma dearance
of the tracers and high target-to-blood ratios for visualizing coronary artery lesions.
The clinical and animal data cleal1y suggest that the accumulation of the tracer in the
lesion may be nonspecific, and radiolabeled IgG may not be an appropriate
radiotracer to image and identify vulnerable atherosclerotic lesions (Sinzinger et al ..
1996).
To overcome the problem of nonspecifIC localization of tgG, various
monoclonal antibodies were developed against different cells and antigens present
in the atherosclerotic lesions. Smooth muscle cells proliferation is one of the major
signals of atherosclerotic disease. A mouse/human chimeric monoclonal IgM
antibody fragment, Z2D3 F(ab'h IgM, with specificity for an antigen associated with
smooth muscle cells was therefore developed (Narula et aI., 1995). 111In-{DTPA_PLr
Z2D3 F(ab'h IgM--negative charge-modified antibody fragments were shown to
-12-
localize in experimental atherosclerotic lesions (Canio et at, 1995).
Focal LOL accumulation in the arterial lesions is predominantly seen in the
edges of regenerating endothelial islands, as reported in a studyon balloon catheter-
deendothelialized aorta of a rabbit (Chang et al., 1992). In 1963, lees et al. (lees
et al., 1983) first demonstrated the diagnostic use of radiolabeled lDL for imaging
carotid atherosclerotic lesions in patients. Subsequently, lDLwas labeled with other
radionuclides with different physical harf-Iives, such as 1231, -'-C alld 1111n, and the
uptake in atherosderotic lesions was demonstrated in a variety of
hypercholesterolemic rabbit models (Sinzinger and Virgolini, 1990: Vallabhajosula
at aI., 1988; Rosen et aI., 1990) and in clinical studies (lees et aI., 1988; Virgolini et
aI., 1991; Vallabhajosula and Goldsmith, 1990; Ginsberg et aI., 1990: Pirch and
Sinzinger,1995). It was observed in patients with carotid atherosclerosis thai the
uptake ofwmrc-LOl occurred mostly in soft, macrophage-rich lesions, whereas the
mature fibrocalcific plaques did not accumulate radiolabeled LDL (lees et aI., 1966:
Virgolini et al., 1991). Some other experiments also showed that macrophagEHich
tissues, induding the tendon xanthomas in hypercholesterolemic patients and the
expanded bone marrow in myeloproliferative patients, cumulated extensive quantity
of radiolabeled LOL (Vallabhajosula and Goldsmith, 1990: Ginsberg et al., 1990).
Even though the potential for diagnostic imaging of radioiodinated LDL and llIlrn'y"c-
LDL was demonstrated in patients with carotid and femoral atherosclerosis (lesion
types Ill-V), clinical use of this technique remains elusive. In coronary arteries,
""-c-LOL imaging does not detect lesions fortwo reasons: the absolute and specific
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uptake of radiotracer in the lesion is very low (<0.1% of the injected dose), and the
blood-pool activity is very high due to slow plasma dearance of the radiotracer.
Many studies have demonstrated that chemically modified LDLs, such as
oxidized LDL (OxLDl) and acetylated LDL (AcLDL) can be taken up by
macrophages more efficiently than native LDL (Ross, 1993). Therefore, OxLOL or
AcLOL labeled with appropriate radionuclides would be expected to be more
selective than radiolabeted native LDL for imaging atherosderotic lesions in vivo.
However, some studies on both patients and animals indicated that although"'"c
uptake in carotid lesions was slightly greater when labeled on OxLDL than it was on
native LDL, there were no significant differences between the two tracers in terms
of their lesion detectability, even though the blood dearance of LDL is enhanced due
to oxidation (Luliano et al., 1996). In the mean time, the aortic focal uptake of
modified LOL was similar to that of native LDL, suggesting that the focal uptake of
LDL in arterial lesions is mediated by specific, oxidation-independent patterns of
charge and polarity (Chang etal., 1993). No report on using radiolabeled AcLDL for
the detection of atherosderotic lesions has yet appeared.
In another recent animal study (Yancey and Jerome, 1998), however, it was
reported that heavily oxidized LDL will result in the LDL containing almost no free
cholesterol or cholesteryl ester. This may partly explain why in the above research
there was no difference in the specificities of OxLDL and LDL. This study also
suggested that mildly oxidized LOL was better than AcLDL in terms of its localization
on macrophages (Yancey and Jerome, 1998).
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Due to the long circulation time of lipoproteins in the blood, the target-to-
background ratio is much higher, which hinders the utilization of them as radio
tracers. Some small peptides. nonnal1y 10-20 amino acids, by contrast are cleared
from the circulation very rapidly. Therefore, they can provide high target-to-
background ratios within minutes after injection. Based on the structure of apo B-
100 protein of LOL, the first synthetic peptide, SP-4, was developed in 1990 (Shih
et al., 1990). In later reports, radioiodinated SP-4 showed significant accumulation
in experimental atherosclerotic lesions (Hardoff et at, 1993). Since then, other
synthetic peptides have been developed (P-199 and P-215) and radiolabeled with
Wrn"fc (Vallabhajosula et aI., 1993). The principal advantage of ""'Tc-labeled
peptides compared to ~c-LOL is that imaging can be perfonned within 1 hour
postinjection because the peptides are cleared much faster than LOL from the
circulation. In pilot studies involving patients with carotid atherosclerotic lesions
documented by ultrasound, ~e-P215 single photon emission computer
tomography (SPECT) images showed some uptake in the atherosclerotic lesions
immediately postinjection (Lees and Lees, 1996). In conditions associated with
endothelial cell injury, the peptide endothelin has been shown to present in vascular
smooth muscle cells and endothelial cells of human atherosclerotic lesions.
Radioiodinated endothelin was shown to accumulate in experimentally induced
arterial wall injurias in rabbits (Prat at at, 1993). Recently, several endothelin
derivatives have been labeled with ~c and have been shown to accumulate in
significant amounts in experimental atherosclerotic lesions in rabbits (Dlnkelbofg et
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al.,1995).
The oonventional nuclear medicine gamma cameras have a resolution of 1.0-
1.5 em for planar and SPEer imaging techniques. In contrast, the positron emission
tomograhpy (PET) cameras provide 4-5 rom of resolution. 18F-labeled FOG, an
analog of glucose. has been used extensively as a radiotracer to estimate glucose
metabolic rates of brain, heart and tumor tissues (Phelps at at, 1978: Strauss and
Conti. 1991). This analog competes with glucose for transport into the cell and is
subsequently trapped within the cell. While investigating the mechanisms of FOG
accumulation in lumortissue, Kubota at at (Kubota at aI., 1994) reported that, within
the tumor, the uptake of deoxygluoose by macrophages was higher than that by
tumor cells. Because atherosclerotic lesions are rich in macrophages, it was
hypothesized that FOG-PET imaging of atherosclerosis may provide a noninvasive
test to image and Quantify the extent of macrophage oontent in an atherosclerotic
lesion. This metabolic tracer showed significant localization in experimental
atherosclerotic lesions ofhypercholesterolemic rabbits (Vallabhajosula at at. 1996).
In addition, histopathological data suggest that the amount of FOG uptake in the
lesion oorrelates with the macrophage density in the lesion (Vallabhajosula et at,
1996). Because FOG clears from circulation rapidly, FOG-PET scans may provide
excellent image Quality with very high target·to--background ratios within 30 min
postinjection. although the high oost of the instrumentation may compromise its
The rationale for the use of photosensitiZers in the treatment of peripheral
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atherosderosis is based upon the selective uptake and retention of the
photosensitizer by atherosderotic plaque as compared to the adjacent normal
arterial tissue (Kessel and Sykes, 1984; Spokojny et aI., 1986). light activation of
the photosensitizer only at the affected site would further increase the specificity of
treatment. Thus, for photodynamic therapy to be applied to the treatment of
peripheral atherosclerosis, delivery of the photosensitizers to abnormal vascular
tissue must be optimized. Allison et al. (Allison et at., 1997) found that
preassociation with lDl and AclDl enhanced accumulation of a benzoporphyrin
derivative, a photosensitizer, in atherosderotic tissue when compared with normal
artery, indicating that light activation could lead to a highly selective destruction of
diseased vascular tissues.
A common drawback of all radiolabeled native products, induding LDLs,
peptides, and immunoglobulins is that once these radiotracers are taken up by the
target tissues, they will be quickly degraded within the Iysomal compartment inside
the cell and then be excreted, which compromises the selectivity of these targeting
tracers for long-term monitoring. Unhydrolizable radiochemicals, however, can be
induced to be intemalized to the target sites and entrapped in these cells for a long
period for observation purposes. Cholesteryl iopanoate (CI) was a compound
synthesized in Dr. Counsell's lab at University of Michigan (Figure 2). This
compound simulates the structure of natural cholesteryl esters (CEs), which are the
major components of LDL core, and was reported to be resistant to in vivo hydrolysis
(DeGalan et aI., 1986). In addition, each CI molecule bears three iodines, which
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provides it a great potential for a high specific radioactivity after these iodines are
exchanged by their radioactive counterparts, such as 1251, lSll, and 1231. A series of
tests of radioiodinated Clan its ability to follow the natural lipid deposit procedure at
the atherosclerotic lesion sites for the purpose of earty detection were perfonned by
fonnulating this compound in saline (DeForge et aI., 1989; DeGalan et aI., 1986;
OeGalan et al., 1988). However, due to the lack oftha selectivity, \251_CI formulated
with saline was not successfully demonstrated to be a promising diagnostic agent for
the ear1y visualiZation of atherosclerotic lesions.
In our lab recently, AcLOL was chosen to be an selective canierto deliver 1~1_
CI into the plaque induced into New Zealand White rabbits' aortae (Xiao et aI.,
1999a). Because LOL, OxlOL and AcLOL have been demonstrated to have
selectivity to atherosclerotic plaques (Luliano et aI., 1996; Chang et at, 1993;
Yancey et al., 1998; Allison et al., 1997), and the hydrophobic core of LOL provides
a large space for retaining foreign hydrophobic compounds, loading labeled CI into
LOL will both improve the targeting specificity for Ct and avoid the disadvantage of
labeled LOL (being degraded after internalization). AclOL was chosen in this test
because it has a much quicker blood clearance than LOL, which would enhance the
tissue-te>-background ratio of radioactivity. Results of this study showed that
incorporating '25I-C1 into AcLOL could significantly enhance the selectivity of this
compound to atherosclerotic lesions on the aorta of rabbits, and 90% AcLOL was
cleared from the blood 30 min postinjection. suggesting that loading radiotrace~ into
AcLOL could be a new approach to detect earty atherosclerosis. Two other
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radiochemicals, 1,3-dihydroxypropan·2-one 1,3-diiopanoate (DPIP. Figure 3) and
cholesteryl1,3-diiopanoate glyceryl ether (C21, Figure 4) are undergoing animal
studies for their potential as radiotracers for the early detection of atherosclerosis
after being incorporated into AcLDL. DPIP has a diglyceride structure, and both
DPIP and C21 have six iodines on each molecule, which could provide double the
specific radioactivity of the compounds than that of CI after radioiodination.
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Figure 3. 1,3-dihydroxypropan-2-one 1,3-
diiopanoate (DPIP)
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Figure 4. Cholesteryl 1.3-diiopanoate glyceryl ether
(e21)
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ObJectives:
The first part of this thesis reports on my work on the unhydrolizable
radiochemicals tested in our lab, induding Cl, DPIP and C21 as the radiotracers and
AcLOL as the carriers, for the early detection of atherosclerosis in rabbits. Among
the different detecting methods compared above, instrumental approaches provide
the easiest and most direct identification of atherosderotic lesions. However. since
instrumental diagnostic methods can identify only the lesions in advanced stages,
while early detection of this disease is crucial for the prevention and treatment,
radioimaging diagnosis is more preferable. With regard to the radioisotopic imaging
techniques. radiolabeled lipoproteins and platelets have shown some dinical
potential as imaging agents. But due to poor target-ta-background and target-to-
blood ratios. these agents are not ideal for imaging coronary or even carotid lesions.
Radiolabeled peptides. antibody fragments and metabolic tracers like FOG appear
to offer new opportunities for nudear scintigraphic techniques in the noninvasive
imaging of atherosclerosis and atherothrombosis. However, quick degradation and
lack of accumulation of these compounds within cells may compromise their
advantages. Unhydrolizable radiochemicals seem to be able to offer significant
diagnostic potential after being loaded into chemically modified lDl, in that both the
selectivity to and the long-term retention of the radioactivity at the atherosclerotic
lesions can be obtained.
The second part of this thesis. entitled "Seal oil markedly enhances the
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transfer of a hydrophobic radiophannaceutical into acetylated IoYi density
lipoprotein", describes the techniques we developed in our lab for the purpose of
significantly enhancing the incorporation rate of hydrophobic compounds into LOLs.
This step is of great importance to the end of using LOLs as carriers to selectively
deliver drugs to the target sites. In this part of the studies, four different
microemulsions containing OPIP. a potential radioimaging probe, were prepared by
means of ultrasonication. The four microemulsions differ in their core lipid
component (triolein, canola oil. squalene. or seal oil). The respective OPIP
microemulsions were incubated with AcLOL and the amountof OPIP transferred into
AcLOL was examined. It was found that the amount of OPIP in the microemulsions
expressed as OPIP/oil (wlw) was dependent on the oore lipid component of the
microemulsion in the order of seal oil (0.19 ±0.04) > squalene (0.15 ±0.02) > canola
oil (0.12 t 0.02) > triolein (0.07 t 0.004). With the exception of canola oil, all
microemulsions were found to be effective in enhancing the transfer of OPIP into
AclDL in comparison with commonly used methods, i.e. direct diffusion and
detergent solubilization. It was found that OPIP in seal oil resulted in the highest
amount of OPlP transferred into AcLDL (309.16 t 34.82 va 203.19 ± 64.51 using
squalene and 151.31 ± 28.54 using triolein, OPIP molecules per AclOL particle).
For the first time, oil isolated from harp seals, a marine mammal that lives in
the deep cold North Atlantic ocean, was studied as a major core lipid component of
formulating pharmaceutical mlcroemulsions. DPIP in seal oil resulted in the highest
amount of OPIP transferred into AclOL, which is likely due to the highest OPIP
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concentration found in this microemulsion as well as the high fluidity of seal oil.
The third part of this thesis, entitled "Incorporation of an 11$l-IabelOO hexa-
iodinated diglyceride analog into low density lipoprotein and high specific uptake by
cervical carcinoma cell lines", demonstrates another use of LDLs as carriers of
radiotracel1;: tumor imaging. The feasibility of LDL for cytotoxic drug transport to
tumor cells has been explored since the 19805, when a number of cancer cell lines
were found to have higher LDL receptor activity than nonnal cells. Such differential
uptake between tumor cells and normal tissues may provide a unique opportunity to
use LDL as a tumor~targeting carrier of radiopharmaceuticals for the clinical
management of cancer. In this study, an l~-Iabeled hexa-iodinated digtyceride
analog, DPIP, was synthesized and incorporated into LDL using a fusion technique
to incorporate approximately 500 I1$I_DPIP moleculesllDL particle. Three human
cervical tumor cell lines, Hela, SiHa, and C-33A. were used to examine the binding
and LOL receptor-mediated uptake of this 125I_DPIP_LDL complex. The 125I~DPIP·
LDL conjugate was specifically bound to and taken up by cervical tumor cells
through an LDL receptor-mediated endocytotic pathway. The results suggested that
this conjugate may be a selective carrier for delivering a hydrophobic
radiophannaceutical to cancers and, particularly, for the diagnosis and therapy of
cervical tumors.
Results of all three parts of this thesis indicate that LDL, although not being
paid the same attention as a drug carrier these days as 15 years ago, still shows
great potential as a drug delivery system.
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Chapter 2. Acetylated Low Density Lipoprotein as a Carrier to Deliver
Radlolmaglng Probes for the Visualization of Early
Atherosclerotic Lesions In Rabbits .
Introduction
The pathogenesis of atherosclerosis is a Iong.tenn process developed in a
complex inflammatory and hyperlipidemic environment (Schwartz et at, 1991). It is
known that therapeutic and/or dietary intervention is usually successful at an early
stage of atherosclerosis. However, angiography, which is the standard method for
the detection of arterial obstruction and stenosis, can only identify advanced
atherosclerotic lesions which usually require surgical intervention. It has also been
suggested that the atherosclerosis is usually more severe than the current diagnostic
methodology predicts (Amett et at, 1979; Vlodaver et aI., 1973). Therefore, it is
important to develop an early and non..Jnvasive detection method of atherosclerosis
to pennit a successful therapeutic and dietary intervention.
Although the etiology of atherosclerosis Is not fully understood, the
involvement of monocytes-macrophages in the arterial intima and their subsequent
accumulation of modified LDL have been well elucidated (Genity, 1981).
MacfOphages in the subendothelial space accumulate cholesteryl esters to become
'Published in part in Pnarmaoeut. Res, (see Xiao et aI., 1999a).
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foam cells (Schwartz. et aI., 1991; Gerrity, 1981), and foam cells with massive
accumulation of cholesteryl esters were observed in atheromatous plaques (Buja et
at, 1983). It is known that macrophages express a scavenger receptor for modified
LDL such as OxLDL and AcLDL (Goldstein et aI., 1979), and that such a receptor
was found to be involved in the formation of macrophage foam cell in vivo (Vla-
Herttuala at aI., 1991). The potential for using LDL with its apa B-l00 protein
radiolabeled, induding 123I·LDL (Sinzinger et aI., 1986; Sinzinger and Angelberger,
1988), '25J.LDL (Roberts et aI., 1983), 1111 n_LDL (Rosen at al., 1990; Nicolas et aI.,
1989), and ~c·LDL (Lees et aI., 1985; lees et aI., 1988; Atsma et at, 1993), as
radiomar1c:ers for the detection of atherosclerosis has been investigated. However,
when lDL is taken up by the targeted cells. it is quickly degraded by lysosomal
enzymes and excreted.
To overcome this problem, we have chosen a cholesteryl ester analogue. CI,
a diglyceride analog, DPIP, and a new compound synthesized in our lab, C21, as
radlotracers. It has been demonstrated that all these three compounds are resistant
to hydrolysis in vivo (Longino at al., 1983; OaGalan etai., 1988; Xiao et aI., 1999a
and unpublished data) and thus are able to accumulate in the targeted tissues. In
addition, since each LDL particle contains 1,500 cholesteryl ester molecules in its
oilycore, incorporation ofhydrophilic radiotracerscan provide more radioactivity than
labeling LDL on its apa 8-100 protein. Based on the role of macrophages in
atherogenesis, we examined the use of AcLDL as a lesion-seeking atherogenic
carrier to deliver radiotracers to the site of the eany lesions for the purpose of eany
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diagnosis of atherosclerosis. New Zealand White rabbits were used and ear1y
atherosclerotic lesions were induced in several modes. The localizations of the
proposed diagnostic probes at the ear1y lesion site were examined and compared.
Materials and Methods
Materials
Thin layer chromatography (TLC) was carried out on silica gel 60, F-254
polyethylene-backed plates (Fisher Scientific) and visualized by UV. Column
chromatography was performed on silica gel-60 (230400 mesh) (Aldrich). High
performance liquid chromatography (HPLC) analyses were performed using a
Beckman system with a Bondclone 10 C18, 150 X 3.0 mm oolumn (Phenomenex).
Radioactivity was measured using a CKB-WALLAC 1277 GAMMAMASTER
automatic gamma oounter. Sodium dodecy1 sulfate polyacrylamide gel
electrophoresis (SOS-PAGE) was performed on a Mini-PROTEI~ II Electrophoresis
Cell (Bio-Rad). Image analysis was done by BlOOUANTl\! System IV.
Carrier-free aqueous Na12!Jj was purchased from Mandel Scientific Company
Ltd. Pivalic acid was obtained from Aldrich Chemical Co. Canada. Sephadex- G-25
was purchased from Pharmacia Biotech AS, Uppsala, Sweden. Poly-Prep·
chromatography columns were obtained from Sic-Rad Laboratories (Hercules, CA).
SOS-PAGE molecular weight standards and Bio-Rad protein assay standards were
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purchased from Bio-Rad laboratories (Richmond, CA). l-a-phosphatidylcholine
dipalmitoyl (1.2-dihexadecanoyl-sn-glycero-3-phosphocholine, OPPC) and Ol-a·
phosphatidylethanolamine dipalmitoyl (1,2-dihexadecanoyl-rac-glycero·3·
phosphoethanolamine. OPPEl were purchased from Sigma Chemical Co. Canada
Seal oil was obtained from Terra Nova Fishery, Newfoundland, Canada.
Methods
Preparation of AcLDL:
Fresh human plasma was obtained from the Canadian Red Cross, S1. John's,
Canada. lOl was isolated as previously described (Schumarker and Puppione,
1986) by the sequential ultracentrifugation of fresh human plasma at 40.000 rpm for
24-40 hours at 8°C using a Beckman l8-M ultracentrifuge and a 60Ti rotor. All LOL
preparations were dialysed at 4°C ovemight against a buffer containing 0.3 mM
EOTA, 150 mM NaCI and 50 mM Tris (pH 7.4). Acetylation of LDL was performed
according to a published method (Basu et a!., 1976). The AcLDL preparation thus
obtained was dialysed at 4°C as described above. Protein concentrations were
determined by the Bradford protein assay method with bovine serum albumin (BSA)
as the standard (Bradford. 1976).
-27-
Preparation of 125/_CI, f25/_DPIP, and f~I_C21:
CI and DPIP were synthesized as described (Seevers et at, 1982; Weichert
et al., 1986). C2l was novelly synthesized in our lab (Figure 5) as follows:
Preparation of DP1P (a) and glyceryl1 ,3-diiopaooate (b): Compounds (a) and
(b) were synthesized as described (Weichert et aI., 1986).
Preparation ofcholestery1 chloride (c): cholesterol (Sg, 0.0129mol) was added
to thionyl chloride (5.5g, 0.046mol, 3.5ml). The mixture was set overnight at 20 OC
and then poured into OAN sodium hydroxide (about 25ml). The product was
extracted three times with ether (1:1), then the combined ether was dried by
anhydrous MgSO~, Ether was then evaporated to afford a sernipure whitish solid,
which was further purified by silica gel column chromatography with hexane as the
elutant. White cholesteryl chloride solid (3.9 g) was obtained with a yield of 76%.
Preparation ofcholesteryl1,3-diiopanoate gtyceryl ether«d), C21): cholesteryl
chloride (55mg, O.14mmol) in2mL of benzene, compound (b) (15Omg, 0.125mmol)
in 2ml of DMF, and potassium hydroxide (17mg. 0.29mmol) in 2mL ofethanollwater
(50:1Jv:v) were mixed. The mixture was refluxed overnight, then the solution was
concentrated in vacuo at 50 "C and cooled at room temperature. White crystals
were generated and purified by column separation (CHC~, silical gel). The yield was
about 12.5% (about 25mg). IR(cm·1): 3500, 3380(-NH2), 2950, 2840(-CH~),
1480(C=C), 1740(-C=O), 1380«CH~)2-CH-), 1600,920 (Ar). lH-NMR(ppm): 8.1(5,
2H, Ar-H), 5.4(s, 1H C=e-H), 4.8(5, 4H, NH:z), 4.1(m, 4H, CH:z), 3.7(m, 2H, -O-CH),
3.4-3.2(m,4H, CHJ, 2.8(m, 2H, CHCOJ, 2.2-1.6(rn, 22H,CH2, CH), 1.1-1.3(m, 10H,
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CHJ, 0.9(d, ISH. CHJ, 0.7(5, 6H, CHJ.
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FigureS Synthesis of choIesteryt 1 J.d... 1I0panoate Ig yc;eryt ether (C21)
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All three radiotracers were radiolabeled with 1251 via an iodine exchange
reaction in a pivalic acid melt (Weichert et aI., 1995). The chemical and
radiochemical purity of 12:5J-CI, l~_DPIP, and 1251-C21 were detennined by HPLC and
TLC (DeGatan et at. 1986).
General procedure of incorporation of 12St_C/, 12sf_DPIP, and 125f_C21 into AcLDL:
A mixture of 12 mg DPPC, 8 mg DPPE, 20 mg seal oil and 1 mg radiolabeled
drug in chlorofonn was dried with a genUe stream of nitrogen, and re-suspended in
10 mL of saline. The suspension was sonicated for 2 hours using a Virosonic Cell
disrupter Model 16-850 at 40-50 watts at about -10 ac. The mixture was then
centrifuged at 40,000 rpm for 20 hours at 4 °C in a Beckman SW41 rotor. The
microemulsion that floated to the top of the centrifuge tube was collected.
Microemulsion thus obtained was incubated with AcLDL at 37 "C for 24 hours. The
resultant mixture was centrifuged again to obtain l:z=1I-CI/AcLDL.
Characterization of 125/-Cl/AcLDL:
Column chromatography: After separation from microemulsion by
ultracentrifugation, l~-CI/AcLDL (about 2 mglmL), 500 mL. was loaded onto a
Poly-Prep· chromatography column packed with about 19 of SephadeX- G-25 and
eluted with phosphate buffered satine (PBS pH =7.4). Fractions of 0.5 mL each
were collected. The radioactivity and protein content associated with each fraction
were determined and plotted.
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Electrophoresis: In order to assess the integrity of the apa 8-100 protein
associated with 1251-CI/AcLOL, the \25I-ClIAcLDL sample was examined by 50S·
PAGE and compared with native LDL and AcLDL as reported (Cardin et at. 1986).
Stability of'~-CI/AcLDLin plasma: 1251_CI/AcLDL was incubated with plasma
according to a reported method (Smadi-Baboli et at, 1993) with modifications. 1251_
CI/AclDL, 1mL, was incubated with 5 mL of human plasma at 37 cC for 24 hours.
Different fractions including very low density lipoprotein (VLDL), lDL, high density
lipoprotein (HOL), and lipoprotein deficient serum (LPDS) were separated as
previously described (Schumaker and Puppione, 1986). The radioactivity in each
fraction was determined.
Animal model and protocol for 125/-eI/AcLDL:
Eight female NewZealand White rabbits (3.204.75 kg)were randomly divided
into two groups. One group was maintained on normal rabbit chow (n=4) and the
other group on rabbit chow supplemented with 1% cholesterol and 2% lard (n=4) for
6 weeks to induce the development of early stage atherosclerotic lesions. The 1251_
CI/AclDL preparation was then injected via the marginal ear vein to both control and
atherosclerotic lesion rabbits at 2 ~CUkg. Blood samples were taken at 5 minutes,
30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours after
injection. The rabbits were then sacrificed and 4% formaldehyde buffer was infused
into the heart to fix the organs. Tissues, including aorta, liver, spleen, lung, kidney
and heart, were removed for determination of radioactivity using a gamma counter.
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The aortae that were free of fat and ronnective tissues were opened
longitudinally. and fixed in 4% formaldehyde for 48 hours. After fixation. the aortae
were stained with Sudan IV solution, and subsequently exposed to Kodak X-
OMATTIol AR film and stored in Kodak X-Omatic cassettes at -70°C for one week.
Animal model and protocol for 1251-DPIP/AcLDL:
Nine male New Zealand White rabbits (3.2 kg - 4.1 kg) were divided into two
groups randomly. Both groups were fed with 1% cholesterol diet for 3 weeks. Then
surgery was performed to induce carotid artery injuries. The 1% cholesterol diet was
maintained for both groups for a further 6 weeks. and in the meantime, an anti-
atherogenic agent was applied to one group (n=5) at 10 mglkg/day. Rabbits were
injected with 2 ~Cilkg '25I_DPIP 24 hours prior to sacrifice. Tissues including liver,
spleen, lung. kidney, adrenal gland. blood. and aorta were separated and counted.
Autoradiogram was performed on the aortae of both groups as described above.
Animal model and protocol for 1251~C2f/AcLDL:
Ten male New Zealand White rabbits (2.5 kg4.7 kg) were randomly divided
into three groups. One group was maintained on normal rabbit chow (n=4. control
group) for twelve weeks. one group on rabbit chow supplemented with 1%
cholesterol (n=4. cholesterol group) for 12 weeks to induce the development ofealiy
stage atherosderotic lesions. and the other group was treated the same as
cholesterol group except for being fed with the anti-atherogenic agent (10mglkglday)
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simultanously (n=2, anti-atherogenic agent group). The 1251_
C21/microemutsionJAclOL preparation was then injected via the marginal ear vein
to all the three groups of rabbits at a dose of 15 1.1 Cilkg. Twenty four hours
postinjection the rabbits were sacrificed and tissues, including liver, spleen, lung,
kidney adrenal gland, blood and aortae, were sampled for determination of
radioactivity using a gamma counter. Results of biodistribution were shown in Figure
9 and Table IV.
In vivo stability tests of DPIP and C21
In vivo stability tests were performed according to a published method
(DeGatan et aI., 1988). Briefly, 10 g liver was homogenized with a Brinkmann
homogenizer (model PT 10/35) for 3 minutes. The homogenate was then extracted
twice by 90 mL CHCI3:CH30H (2:11v:v). The extract was filtered and evaporated.
The residue was then analyzed by TLC with CHCI3:CH30H (25:2 Iv:v) as the
development solution. The plates was cut into ten O.Scm pieces. The stability was
expressed as the proportion of the radioactivity associated with the DPIP orC21 spot
out of the total radioactivity of the ten pieces.
Results and Discussion
It is clear that macrophages play an important role in the formation of
atherosclerotic lesions (via the formation of the foam cells) (Schwartz et al., 1991;
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Geniy, 1981; Buja et at, 1983; Y1a-Herttuala et at, 1991) and they express
scavenger receptors that mediate the uptake of AclDL It is believed that CI
incorporated into AcLDL (CI/AcLDL) is taken up by macrophages (Kenji etat., 1988)
through the scavenger receptor pathway. We have, therefore, examined the
potential of using AcLDL to deliver radiotracers, such as cr, DPIP and C21, to early
atherosclerotic lesions induced in rabbits. These radiotracers can be easily labeled
with 1311 or 1231, and will arrow the visualization of the lesions using gamma
scintigraphy technology if the proposed method can selectively target these tracers
to the lesion sites.
Preparation of 12S/-eVAcLDL
1251-C1 was synthesized and its radiochemical purity was found to be more
than 96%. Microemulsions have been widely employed in loading drugs into LDL,
and in our studies, seal oil was novelly used to form microemulsion for its high
effICiency of transferring the drugs to LDL (Xiao et at. 1999b), presumably because
seal oil contains high levels of highly unsaturated triglycerides, which may allow for
high solvation of hydrophobic drugs and the increase of fluidity. With the loading
method we employed, up to five hundred 12S1-C1 molecules can be incorporated into
each AcLDL particle (>Gao et al., 1999a). The specific radioactivity of the 12151_
Cl/AclDL was about 2.5 I-lCilmL
Characterization of 12S/-CVAcLDL
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Figure 6. Chromatograms of gel filtration of 125I-eUAcLDL preparation with
respect to its radioactivity (<0) and protein concentration (0).
Figure. 7 Distribution of radioactivity upon incubation of 125I·CI/AclDL with
plasma. Values are the % of initial radioactivity associated with individual fractions
after incubation.
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Analysis o(anima' data (or f15f-CVAcLDL Imaging
Although there are many published methods on generating atherosclerotic
lesions in rabbits (Roberts et al., 1983; Atsma et a1.. 1993; Narula et a!., 1997;
Allison et aI., 1997), early atherosderosis was induced in New Zealand White
rabbits in this case by feeding a regular diet supplemented with 1% cholesterol and
2% lard for six weeks while the control group was maintained on a regular diet.
Cholesterol. triglyceride. HDL. and LDL levels in blood were measured in.,....QQ!.h
control and atherosclerotic groups. The results are summarized in Table 11. The
atherosclerotic group demonstrated increased levels of aU lipids measured. 1251_
Cl/AcLDL was then given intravenously to both control and atherosclerotic groups
at 2 ~CjJkg. The radioactivity in blood samples taken at different lime intervals was
measured. The results presented in Figure 8 and Table III demonstrated that the
clearance of 1zsl_CI/AcLDL from blood follows a two compartment model with t11'2a
of 0.28 hr and 1.09 hr and tU2\lof 56.60 hrand 43.79 hr for atherosclerotic and control
groups, respectively. The difference in t1/2 values between two the groups was not
significant (p>O.05).
-39-
Table II. Comparison between atherosclerotic and control rabbits of cholesterol,
triglyceride, HDL and LOL contents in blood. (Average t SO)
Atherosclerotic group Control group
Cholesterol (mmoVL) 60.01 t 8.79 0.57 t 0.12
Triglyceride (mmoVL) 4.90 t 2.67 0.69:t. 0.04
HDL (mmollL) 18.65 t 3.00 0.37:t 0.01
LDL(mmoVL) 39.13 ± 4.57 O.16±O.08
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Figure. 8 Amount of '"I·CI in blood versus time after 1.'1. injection of l"I_CI at 2
IJCilkg in atherosclerotic (e,.) and control rabbits (0,6). n-4.
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Table III. Pharmacokinetic parameters of the radioactivity In the blood of
atherosclerotic and control rabbits atter i.v. injection of 12'5I·CI/AclOL
at 2 ~Cilkg dose. (Average t SO)
t,.(hrJ .... /hr.}
ControlllfOUP O.70t 0 ?3
k"..k,: e1iminalionconstanl
1t/2: drug halfHfe in blood
V: Volume of distritxJlioo
CL:Clearance
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The tissue distribution studies suggested that there were no significant
differences between the atherosclerotic group and control group in alt tissues with
exception of the aorta and blood at 72 hours. The radioactivity in both aorta and
blood expressed as percent of injected dose per gram of organ, was about 8 times
higher for the lesion group than for the control group (Figure 9 and Table IV). The
increased radioactivity level in the aorta of atherosclerotic rabbits was likely due to
the higher level of scavenger receptor which mediates the uptake of AclDl in the
lesion sites. The higher levels of 1251-e1 in blood for this group of animals can be
explained by their higher blood cholesterol levels (Table II). From Figure 10. it was
found that the lesion areas which correlated with the autoradiography was about 5%
of the total aorta. The specifIC radioactivity of the lesions of aorta was the highest
among all the tissues taken, including liver and spleen (Table IV). Thus. we have
shown that using AcLDL as a targeting carrier to atherosclerotic plaques achieves
a high accumulation of '25j-e1 at these sites, as shown by the presence of the most
radioactive spots in the lesioned areas among the major organs examined.
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Figure 9. Distribution of radioactivity in various tissues expressed as % of
administered doselg tissue (left) or % of administered doseJwhole tissue (right) in
atherosderotic and control rabbits after i.v. injection of '~-CI/AcLDLat 2 IJCVkg.
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Table IV. Comparison between atherosderotic and control rabbits of distribution
of radioactivity in various tissues after Lv. injection of l~I..cI/AcLDLat
2 ~Cifkg. (Average:l: SD)
Tissue Atherosclerotic group (n=4) Control group (n=4)
% administered dose/g tissue % administered doseJg
tissue
LIVER 0.46:1: 0.29 0.68:1: 0.068
SPLEEN 0.98:1: 0.87 1.04:1: 0.57
LUNG 0.21 :1:0.14 0.20:1: 0.17
HEART 0.060 :I: 0.017 0.062:1: 0.032
AORTA 0.056 :t: O.034a 0.0069 to.0019
KIDNEY 0.057:1: 0.022 0.032 :I: 0.017
BLOOD 0.087 :t: 0.030a 0.013:t: 0.0073
a p <0.05
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Figure 10. Correlation of Sudan IV staining (left) and autoradiography (right)· CI.
Sudan IV staining was carried out on the aortae In order to visualize the
atherosclerotic lesions. The red lipid stain is an indication of lipid·laden foam cells,
a hallmark of ear1y atherosclerosis. As shown in Figure 10, the lesion area
corresponded to about 5% of the whole aorta. The most severe lesion region was
the ascending aorta at the aortic arch. Blood flow through this section of aorta is
turbulent due to the curve of the aortic arch and the three large branches. The
highest incidence of human atherosclerosis is to be found in this region of the aorta.
The hottest spots detected in the aortae of lesioned rabbits were strongly correlated
to the location of highest incidence of human atherosclerosis.
Autoradiographs of aortae removed from both normal and atherosclerotic
rabbits are shown in Figure 10. The image was the result oftha accumulation of 1251.
ClIAcLDL. The area of the image superimposed with the staining result, suggesting
125I_CI/AcLDL has been taken up by the lesion. 80th Sudan IV and autoradiography
showed negative results with the aorta from control rabbits.
Results of using IlSl-DPIPIAcLDL complex as the radiotracer
125I·DPIP was selected as an alternative to l~..cl because each DPIP
molecule has two benzene rings, and each of its benzene rings carries three iodines.
Since about same amount of DPIP was incorporated into AcLDL as CI (unpUblished
data), DPIP has the potential of bearing 6 radiolabeled iodines and having higher
specifIC radioactivity than Cl, which presumably makes it a more attractive candidate
for the purpose of this study. Extraction of DPIP from livers of rabbits showed that
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87% of the radioactivity was associated with DPIP. indicating that OPIP is chemically
stable in vivo (unpublished data). However, according to our animal test with 1251.
DPIP/AclDL, although a difference between the drug tissue distribution of the anti-
atherogenic agent treated group and cholesterol diet group was observed (Table V
and Figure 11), indicating that the anti-atherogenic agent could alleviate the
procedure ofatherosclerosis in rabbits. the autoradiograms were not clearly showing
any difference between the lesions suggested by Sudan IV staining (data not
shown). In addition, compared with 125I·CI, less 125I·OPIP was found in all rabbit
tissues even though the administered radioactivity for 125I·DPIP and 125I_CI were the
same, and the observation time was shorter (1 day for 125I·DPIP and 3 days for 1251_
Ct). A possible explanation to this is that DPJP, compared with CI. has a much
smaller molecular structure, and a higher hydrophiticity. Therefore, higher levels of
125I_DPIP may have been excreted through the renal clearance system.
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TableV. Comparison betoNeen atherosderoticand control rabbits of distribution
of radioactivity in various tissues after i.v. injection of ,2$I.OPIPJAclOL
at 2 ~CiJkg. (Average ± SO)
Tissue Anti-atherogenic agent treated Cholesterol diet group (n:4)
group (0=5) % administered doseJg tissue
% administered dose/g tissue
liver 0.091 :I: 0.018 0.15 :I: 0.024
Spleen 0.082 :I: 0.015 0.096 ± 0.021
lung 0.023 :I: 8.7x10" 0.052 :I: 8.1x10"
Adrenal 0.098 :I: 0.015 0.11 :I: 0.017
Kidney 0.065 :I: 0.024 0.089:1: 0.020
Blood 0.068 :I: 0.040 0.11 :I: 0.054
Aorta 0.00069 :I: 0.00012 0.0073> 0.0066
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Figure 11. Distribution of radioactivity in various tissues expressed as o/e> of
administered dose/g tissue in atherosderotic and control rabbits after i.v. injection
of \~I-DPIP/AcLDLat 2 IJCiltc.g.
f 0.12
"& 0.10
i''"
;;t 0.06
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Results of using fl'I-C2VAcLDL complex es the radiotracer
To combine the advantages of CI and DPIP, and overcome the drawbacl<. of
DPIP, we have designed and synthesized a new compound, C21. C21 combines the
structure of DPIP, which provides six iodines for radiolabeling (twice of those on CI),
and a backbone ofcholesterol, which enhances the hydrophobicity of the compound,
so as to avoid the renal clearance of the drug (Figures 2-4). In the molecule ofC21,
the cholesteryl part and the diglyceride part are linked via an ether bond, which is
resistant to the hydrolysis by lysosomal enzymes in cells. Therefore, the compound
is expected to be stable in the cytoplasm and subcellular compartments. In vivo
stability test showed that 91.2% of the radioactivity in liver cells was still associated
with C21 (see Materials and methods), indicating that C21 is chemically stable in vivo.
It was found that there was no statistical difference between the anti-
atherogenic agent treated group and cholesterol fed group in terms of the
localizations of 1251-C21 in liver, spleen, lung, kidney, adrenal gland, blood and aorta,
indicating that the anti-atherogenic agent had no effect on the distribution of 1~1-e21
in rabbits within 24 hours (Figure 12, Table VI). While the localizations of 1251-C21 in
adrenal gland for both the anti-atherogenic agent and the cholesterol group were
significantly lower than that in control rabbits (p<O.05), and the distributions of 1251_
C21 in blood and aortae of the anti-atherogenic agent and cholesterol group were
significantly higher than those for control group (2 to 4 times, Figure 12 and Table
VI). In autoradiography studies, lesions were clearly shown and in correlation with
the Sudan IV staining results, and the places without lesion did not show any image
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on the film, indicating that 1251-C21 was selectively located at the aortic plaques
(Figure 13).
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Figure 12. Biodistribution of 1251·C21 in the anti-atherogenic agent group,
cholesterol group, and control group rabbits.
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Table VI.Comparison between atherosclerotic and control rabbits of distribution of
radioactivity in various tissues afteri.v. injection of'~1-C21 at 15 ...Cilkg in the
anti-atherogenic agent group, cholesterol group, and control group rabbits
(Average ± SD).
Anti-atherogenic Cholesterol group Control group
agent group (Aa) (Ch) (Co)
% administered % administered % administered
dose/g tissue doselg tissue doseJg tissue
Liver O.38±O.097 O.37to.06t 0.5O±O.O30
Spleen 0.57±O.t3 0.63±O.090 0.74±O.10
Lung 0.39±O.t6 0.33±O.075 0.23±O.060
Kidney 0.10to.Ot2 O.O77±O.OO9O 0.079tQ.014
Adrenal Gland O.20t0.012 0.23to.0091 0.62to.12
Blood O.3O±O.O76· O.20to.029 O.074to.015
Aorta 0.0065%0.0039 0.0070±0.0012 O.OO33±O.OOO67
. Significant difference compared with controls, p<O.05
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Figure 13. Correlation of Sudan IV staining (left) and autoradiography (right) ~ C21.
Lesion Aorta
Control Aorta
-
Conclusion
Ourstudies demonstrated that selective uptake and retention of 1251-C1 at the
site of eat1y atherosclerotic lesions can be achieved via the use of AclDl as the
carrier. This finding warrants further animal studies. 12:51·DPIP also revealed
differences between the drug distributions oftwo rabbit groups with differentdegrees
of atherosclerosis. However, because of its high hydrophilicity, the high specific
radioactivity of DPIP may be compromised by its quick renal clearance. 1251-e21 is
promising as a new radiotracer compound forthe early diagnosis ofatherosclerosis.
Its advantages are its higher specific radioactivity, compared to 1251CI, and higher
hydrophobicity, compared to 125I·DPIP. Further studies will be concentrated on
replacing 1251with 1311or 1231in 125I·CI or 1251-e21 to acquire imaging pictures of rabbits
extracorporeatry using gamma scintigraphy.
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LDL or AcLDL particles (Samadl--Baboli et at, 1990; Vitals et aI., 1990; Uu and Uu,
1995). In this chapter. we report on the transfer of DPIP into AcLDL ....ia the
preparation of DPIP microemulsions using triolein, canala oil, squalene, and seal oil
as the core lipid component. The amount of DPIP transferred from the
microemulsions to AcLDL was detennined and compared. For the first time, seal oil
was used to formulate microemulsions. The harp seal, a marine mammal, Ii....es in
an extremely cold en....ironment (-40 to ~70 DC). In such a cold condition, its
circulatory system can stilt function well and its hydrophobic lipids such as
triglycerides, cholesterol and cholesteryl esters remain in liquid state but not
crystalized. Although little research has been done to explain this fascinating
phenomenon, it has been speculated that the unique polyunsaturated long chain
fatty acids found in seal oil may contribute to greater fluidity of hydrophobic
compounds in harp seals at the extremely low temperatures. In addition, seal oil has
strong anti-oxidant properties which are useful in formulating stable microemulsions.
Materials and Methods
Materials
TlC was carried out on Fisher ScientifIC silica gel 50, F·254 polyethylene-
backed plates and ....isualized by UV. HPLC analyses were performed using a
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Beckman system with a Phenomenex Bonddone 1OC18. 150 X 3.0 mm column.
Radioactivity was measured using a CKB·WALLAC 1277 GAMMAMASTER
automatic gamma counter. SOS-PAGE was performed on a BIC-RAO Mini·
PROTEIN" II Electrophoresis Celt. A Philips EM 300 was used for electron
microscopy (EM) and particles were negatively stained with 1% uranyl acetate.
Image analysis was done by BIOaUANTTtol System IV.
Carrier-free aqueous solutions of Na'251were purchased from DuPont NEN
Research Products (Boston. MA). Pivalic acid was obtained from Aldrich Chemical
Co. Canada. Sephadexe G-25 was purchased from Pharmacia Biotech AB,
Uppsala, Sweden. Poly-Prep· chromatography columns were obtained from Bia-
Rad Laboratories (Hercules, CA). SDS·PAGE molecularweight standards and Bic-
Roo protein assay kits were purchased from Bic-Rad Laboratories (Richmond. CA).
DPPC, DPPE. and squalene were purchased from Sigma-Aldrich Canada. Canola
oit was purchased from a local supermar1<et. Seal oit from harp seal. Phoca
groenlandica. was obtained from Terra Nova Fishery Ltd.• Newfoundland, Canada.
Methods
Preparation ofDPIP and 125f-DPIP
DPIP was synthesized as reported (Weichert et at.. 1986) and radiolabetled
wTth 1251via an isotope eXchange reaction in a pivalic acid melt (DeGalan et at..
1988). The chemical and radiochemical purity of '251_0PIP were determined by
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HPLC and TLC as described before (DeGalan et aI., 1988).
Preparation of DPIP microemufsions
OPIP microemulsions were prepared using triolein, canola oil. squalene. and
seal oil, respectively, as the core lipid component. DPPC (12 mg), DPPE (6 mg).
triolein, canola oil, squalene. or seal oil (20 mg), DP1P(10 mg) and 12SI_DPIP(0.05
rng) were dissolved in chlorafonn. dried with a genUe stream of nitrogen. and
suspended in 10 ml of saline at 25°C. 12$I_DPIP was used as a radioactive tracer
for analysis. The suspension was sonicated for 2 hours with a Virasonic Cell
Disrupter Model 16-650 at 40.50 watts while being cooled in a -10 OC salt-ice-water
bath under a nitrogen stream. The mixture was then centrifuged at 40,000 rpm for
20 hours at 4 OC using a Beckman SW41 rotor and a Beckman L5-65 ultracentrifuge.
The microemulsion which floated to the top of the centrifuge tubes was collected,
and subjected to EM and image analysis. The amount of OPIP in the individual
microemJlsions was detennlned using a CKB-WAlLAC 1277 GAMMAMASTER
automatic gamma counter.
Preparation of AcLDL
Fresh human plasma was obtained from the Canadian Red Cross Society, St.
John's, Newfoundland, Canada. lDl was isolated as previously described
(Schumaker and Puppione. 1966) by sequential ultracentrifugation of fresh human
plasma at 40,000 rpm for 24-40 hours at 6 °C using a Beckman l6·M ultracentrifuge
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and a 60Ti rotor. LOL was dialysed at 4 °C overnight against a buffer containing 0.3
mM EDTA, 150 mM NaG! and 50 mM Tris (pH 7.4). Protein concentrations were
determined by the method of Bradford (Bradford, 1976). Acetylation of LOL was
performed as described by Basu and Goldstein (Basu et at, 1976). AclOl was
dialysed and protein concentrations were determined.
Incorporation of DPIP into AcLDL
The 1'l5I-DPIP microemulsions were incubated with AcLOl at 37 OC for 24
hours at a molarratioofDPIPto AclOLof1000:1. AcLOlloaded with l'l5I_DPIP CZ5I_
DPIP/AcLOL) was then separated from mlcroemulsions by Ultracentrifugation as
described (Schumarkerand Puppione, 1986). The DPIP content in 125I-DPIP/AclOL
was determined by y-counting.
DPIP was also incorporated into AclDL using direct diffusion (Shaw et at,
1988) and detergent solubilization (DeForge et at, 1992) with minor modifICations.
In brief, for the method of direct diffusion, OPIP was dissolved in chlorofonn in a
glass vial and dried under a stream of nitrogen to form a thin film on the wall of the
vial. AclOl was added to the vial and incubated at 37 OC for 24 hours. For the
method of detergent solubilization, OPIP was dissolved in saline in the presence of
Tween 20 «3%), and incubated with AcLOl at 37 Of: for 24 hours. The molar ratio
of OPIP to AclDl used remained the same as above.
Characterization of f'15/_DPIPIAcLDL
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1251-0PIP/AclDl (500 ml), about 1mglml, was loaded onto 19 of SephadeX-
G·25 in a Poly·Prep· chromatography column and eluted with phosphate buffered
saline (PBS pH 7.4). Fractions of 0.5 ml were collected, and radioactivity and
protein content of each fraction were measured and plotted.
In order to assess the integrity of the ape B-1 00 protein of 12SI_OPIP/AclOl,
samples were analyzed by 50S-PAGE and electron microscopy (EM) as described
(DeForge et aI., 1992).
Results and Oiecuulon
Our previous studies suggested that AclDl could be used as a carrier to
deliver radiolabelled CI, a cholesterol ester analog, to atherosclerotic lesions in
rabbits (Xiao et aI., 1999). Compared to el, DPIP is considered to be a better probe
for the detection of atherosclerotic lesions. Through radio-iodination, the six iodine
atoms on each DPIP molecule provide higher specific radioactivity than CI. This is
desirable for the accumulation of the high radioactivity required for diagoostic
purposes. In this report, the loading of OPIP into AclDl was studied.
The methods ofdirect diffusion and detergent solubilization have been widely
used for loading lipophilic drugs into lDl orAcLDl dueto their simplicity (Firestones,
1994). Microemulsions have also been employed to transfer various drugs into lDl
or AclDl (Samadi.Baboli et al.,1990; Vltols et al.,1990; liu and liu,1Q95; SqaUi-
Houssaini et at,1994), and so far triolein has been one of the most commonly used
core lipid components. In this study, squalene and seal oil were used as the core
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lipid components ofmlcroemulsions for the first time. Squalene, a highly unsaturated
hydrocarbon (C:lOHilO) that is an intennediate product in the synthesis of cholesterol,
was shown to be capable ofre-supplying cells with much needed oxygen. In recent
years, seal oil has been of interest for its potential use in the maintenance of human
health (Simopoulos, 1991; Christensen et at., 1994; Osterud et at., 1995;
Christensen and Hoy, 1996). The (a)·3 polyunsaturated long chain fatty acids found
in seal oil have been shown to be beneficial in lowering blood pressure (Bonaa et al.,
1990), reducing triacylglycerols (Hams et at, 23), and modulating celt function and
cell reactivity to external stimuli (Fox and Dicor1eto, 1988). In addition, seal oil
appears to be very resistant to oxidation, which is desirable for preparation of stable
microemulsions.
The preparation of the microemulsions was carried out by hydrating a dried
film of the lipid mixtures with saline at room temperature. This was followed by
ultrasonlcation, during which the aqueous dispersions were cooled in a salt-ice bath
at -10"C to prevent overheating due to the sonication. It is possible that the
preparation of the microemulsions at a temperature below the gel-liquid crystalline
phase transition temperature of the phospholipids would result in limited hydration
of the phospholipids. However, the electron micrographs show structures that are
typical of those observed in preparations of microemulsions formed by sonication at
temperatures above the phospholipid transition temperatures (Redgrave and
Maranhao, 1985). FurthelTTlOfe, these authors reported that the microemulsion
particles were 5O-200nm in diameter. This compares well with our preparations that
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have diameters of 3O-90nm (Figure 15). The slightly larger diameter seen by
Redgrave and Maranhao could be due to the use of a phosphatidyicholine species
containing unsaturated fatty acids that increase the molecular area of the
phospholipid compared with the fully saturated phosphatidylcholines that were used
in our preparations.
The concentrations of OPIP in microemulsions with triolein, canola oil,
squalene and seal oil as the oore lipid oomponent were compared. It was found that
the amount of OPIP eventually loaded into the microemulsions expressed as
OPIP/oil (wlw) was in the order of seal oil (0.19:1: 0.04) > squalene (0.15:1: 0.02) >
canala oil (0.12:1: 0.02) > triolein (0.07:t 0.004) as shown in Figure 14. EM (Figure
15) and image analysis (Figure 16) results showed that the size afthe microemulsion
particles is in the same order of seal oil (longest diameter = 67.8 :I: 25.37 nm) >
squalene (longest diameter = 58.2:1: 22.01 nm) > canola oil (longest diameter =52.9
± 16.05 nm) > triolein (longest diameter = 40.6:1: 13.5 nm).
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Figure 14. Comparison of DP1? concentrations in microemulsions using triolein,
canala oil. squalene and seal oil, respectively, as the core lipid component. The
results are expressed as the ratio of OPIP to oil (wtw).
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Figure 15. Electron micrographs ofDPIP mlcroerrolsions using triolein (A), canola
oil (8), squalene (el and seal oil (D), respectively, as the core lipid component. All
panels are shown at the same magnification.
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Figure 16. Image analysis of DPIP mlcroemulslons using triolein, canala 011,
squalene, and seal oil, respectively, as the core lipid component. The left four
panels are the distributions of Image areas of four microemulsions (nm2) and the
right four panels are the distributions of longest diameters of the four microemulsions
(nm). See next page.
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Upon incubation of the DPIP microemulslons with AcLOl, DPIP was
successfully transferred into AclDL. with the exception of the canola oil
microemulsion. in which AclOl was found to be aggregated (data not shown).
OPIP/AcLOL preparations were subjected to gel filtration. The chromatograms of
radioactivity and protein contents were plotted. As shown in Figure 17, radioactivity
(due to 1251_0PIP) and protein content were superimposed, suggesting that OPIPwas
transferred to AclDL (or OPIP/AcLDL formed). 50S-PAGE results of DPIP/AclDl
indicated that the integrity of apo 8-100 protein was intact in comparison with native
lDL and AcLDL (data not shown). The poor results obtained with canota oil are
possibly due to the presence of preservatives or other additives in the commercial
canola oil.
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Ftgure 17. Confinnation of l~.DPIPincorporation intoAcLDL particles using three
differenllipid microemulsions (top panel: triolein; middle panel: squalene; and bottom
panel: seal oil). 125I-DPIP/AcLDL conjugates were analyzed by gel filtration
chromatography through Sephadex G·25 with PBS. The radioactivity and protein
content of each fraction were detennined as described in the section of Materials
and Methods. See next page.
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The transfer efficiency of DPIP from the triolein, squalene, and seal oil
microemulsions to AclDL was also compared with Vlat of two commonly used
methods, i.e., direct diffusion and detergent solubilization. As shown in Figure 18,
the amount of DPIP transferred into AclOL through the different DPIP
microemulsions was higher than that through direct diffusion (27.70 ± 1.99 DPIP
molecules lper AcLDL) and solubilization (66.97 ±1 4.81 DPIP molecules lper
AcLDL). Among the microemulsions studied, the seal oil microemulsion resulted in
the highest amount of DPIP transferred into AcLDL (309.16 ± 34.82 vs 151.31 ±
28.54 using triolein and 203.19 ± 64.51using squalene expressed as DPIP
moleculeslper AcLDL). The similar trend found in Figure 14 and Figure 18 suggests
that the concentration of DPIP found in the microemulsion is the decisive factor for
the transfer of the drug into AcLDL
A possible explanation for these observations may lie in the differences in the
physical behaviour of the different core lipids. Seal oil contains high levels of highly
unsaturated triglyceooes. These may allow for solvation of more hydrophobic DPIP
than triolein and may also, because of increased fluidity, allow for more rapid transfer
of DPIP to the lipoprotein particles.
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Figure 16. Comparison of the DPIP loading efficiency into AcLDL using different
methods. Results are expressed as DPIP/AcLDL (moIImol).
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Conclusion
To load OPIP into AcLDL, we prepared different DPIP microemulsions
including the use of seal oil and squalene for the first time. We found that all OPIP
microemulsions resulted in a higher OPIP incorporation into AcLOL than the two
commonly used methods. More interestingly, OPIP microemulsion prepared using
seal oil and squalene loaded more OPIP into AcLOl than that prepared using
triolein, which is likely the result of the higher OPIP concentrations found in seal oil
and squalene microemulsions. It is, therefore, suggested that seal oil and squalene
may be used as substitutes for triolein in the manufacturing of microemulsions in
pharmaceutical industry. Obviously significant studies, such as tests of safety and
stability of these marine mammal oils, are required.
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Chapter4. Incorporation ofan t~-1abeJed hexa-lodlnated dlglycerlde analog
Into low density lipoprotein and high specific uptake by cervical
carcinoma ceil lines-
introduction
LDL is the predominant cholesterol transport vehicle in human blood. For
each LDL particle. a hydrophilic shell surrounds approximately 1.500 molecules of
choiesteryl esters in its lipophilic oore. TIssue LDL uptake occurs through a pathway
mediated by a specific cell surface LDL receptor. A protein unique to LDL particles,
apo B-100. binds to this receptor. followed bycellular intemalization and degradation
of the particles. Cholesterol is then released for synthesizing and maintaining the
various cell membranes (Brown and Goldstein. 1986). A number of tumor cell lines
were found to have higher LDL receptor activity than normal cells (Ho et at. 1978;
Galetal.. 1981; Vitols etal.. 1985; Rudlingetal.. 1986; Rudling et aI., 1990). Taking
advantage of this preferential LDL acctJmulation. researchern have examined the
utility of LOL as a vehicle for transporting cytotoxic drugs to tumor cells since 1981
(Gal et al.. 1981: lwanik et al.. 1984; Masquelieret al.. 1986; Lundbert. 1987; Vitals
et al., 1990; Samadi-Baboli et 81.• 1990: Firestone. 1994). Although the usefulness
of LOL as a carrier for antitumor agents has been extensively studied, little is known
"'Published in Radisf. Ras.(see Xiao at al. 1999c)
-75-
regarding the accumulation of drug-lDL conjugates into tumors, and few animal or
cancer patient studies were encouraging (De Smidt and van Berkel, 199O(a); Vitals
et al .. 1992; Panty et at, 1993).
LDL has potential to also be an effective delivery vehicle of
radiopharmaceuticals for tumor diagnosis and radiotherapy, because tumor cells
have an elevated level of LOL receptors. This potential has generated some recent
interest from researchers. There are two approaches to introduce radionuclides to
LDL. One is to directly or indirectly link radionuclides. such as t9m'fc, \2$1 or 12:51_
tyramine cellobiose, to apa B-1oo ofLDL (Panty et al .• 1993: Leppala et al.. 1995;
Pittman and Steinbert, 1978). The other is to label LDL with a radionuclide through
an LDL lipid-chelating agent (Jasanada et aI., 1996: Urizzi et aI., 1997). However,
three major deficiencies of these approaches are that fiXillQ radionudides onto apa
B-100 may impair its binding to the LDL receptor: few radioisotopes can be used to
label LDL; and most LDL taken up by cells is degraded in the lysosomal
compartment and metabolites are rapidly secreted from the cell. DPIP. 8 hex8-
iodinated glyceride analog, was found to be resistant to lysosomal enzymes
(Longino at a1.. 1983; Weichert at at. 1986; DeGatan at a!.. 1988) due to the
presence of the ethyl group next to the ester bond. Therefore, in this study, we
attempted to circumvent the deficiencies of labeling apa B-1oo or LDL. by
synthesizing DPIP, labeling it with \251, and then incorporating it into LDL (forming
'~-DPIP-LDL conjugates) using 8 fusion technique. Three cervical cancer cell lines.
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HeLa, SiHa, and C-33A, were used to evaluate the LDL receptor-mediated uptake
of 12SI_DP1P_LDL conjugates bycancer cells. The LDL receptor numbers and binding
constants of SiHa and C-33A were also determined.
Materials and Methods
Preparation of LOL, LPOS and AcLDL
LDL and LPDS were isolated from human plasma (Canadian Red Cross, St.
John's, Canada) by sequential density gradient ultracentrifugation, as previously
described (Schumaker and Puppione, 1986), and stored at 4°C forup totwoweeks.
For the preparation of AcLDL, acetylation of LDL was performed, as described by
Basu and coworkers (Basu et at, 1976). LDl, LPDS and AcLOL were dialyzed at
4°C for 16 hours in a buffer containing 0.3 mM EOTA, 150 mM NaCI and 50 mM
Tris-HCI, at pH 7.4. ForLDL receptor binding experiments, apo B-1oo ofLDL was
labeled with ,~ directly to its tyrosine residues by incubating LDL with lod~Beads
(Pierce, Rockford, IL) in the presence of Nat251at room temperature for 5 minutes.
t2SI_LDL was separated from free Na t:lS1 by a Sephadex G-25 column.
Preparation of 12S/_DPIP_LDL
DPIP was synthesized using previously reported methods (Longino et aI.,
1983) and labelled with 1251 via an isotope exchange reaction with carrier free
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aqueous Na'251(Mandel Scientific Company ltd.• Guelph, Canada) in pivalic acid
(Aldrich Chemical Co., Burlington, Canada) (Weichert et aI., 1986; DeGalan et at,
1988). The chemical and radiochemical purity of 125I_DPIP thus obtained was
detennined by TLC and HPLC using a Beckman Gold system (Fullerton, CAl with
a Phenomenex Bondclone10 C18 column (Torrance, CA).
To prepare125I_DP1P_LDL, 125I_DPIP microemulsion was first prepared. 12 mg
DPPC, 8 mg DPPE (Sigma Chemical Co., Burlington, Canada), 20 mg seal oil (Terra
Nova Fishery, St. John's, Canada) and 10 mg 1251_0PIP were dissolved in
chlorofonn, dried under nitrogen flow, and suspended in 10 mL of saline. The
suspension was sonicated for 2 hours at about-10°C under a nitrogen stream. The
mixture was then centrifuged at 200,OOOg for 20 hours at 4"C. The floating
microemulsion was collected.
125I_DPIP microemulsion was then incubated with LDL at 37°C for 24 hours at
an 1251_0PIP to LDL molar ratio of 1000:1. 125I-DPIP_LOL was then purified by
uftracentrifugation, as described previously (Schumaker and Puppione, 1986).
Characterization of 125/_DPIP-LDL
The purityofl25I_0PIP_LDLwas analyzed bySephadex G·25 chromatography
in PBS. To assess and compare the Integrity of apa 8-100 in native LOL with that
in LDL loaded with 1251_OPIP, apa 8-100 in both types of particles was analyzed by
sUWling the bands obtained with SOS-PAGE. The effect of loading 1251_0PIP on the
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morphology of LDL particles was analyzed by EM. as described previously (Kader
at ar., 1998).
Delennination of receptor tevel, binding dissociation constant and cellutar uptake
of '~/~DPIP~LDL
Exponentially growing Hela, SiHa, and C-33A celts were maintained in
Dulbecco's modified Eagle's medium containing 10% of fetal calf serum (FCS). The
maximum LDl receptor number/cell (B......) and binding dissociation equilibrium
constant (~) of lDL receptor were assayed, as described previously (Goldstein and
Brown, 1974), with minor modification. To up-regulate the levels of LOl receptor,
3 x 105 to 106 cel1sJweJl were plated into 8~well culture dishes and incubated in lPDS
medium for 1 day for HeLa and C~33A or 2 days for SiHa. Then, cells were
harvested at 4°C in various 12'5I·LDL concentrations in the absence or presence of
20~fold excess unlabeled LDl. After incubating Hela and C~33A for 4 hours and
SiHa for 8 hours, the cells were first washed thrice with 1 ml ice-cold 150 mM NaCl,
50mM Tris-HCI, pH 7.4, 2 mglmL BSAand then thrice with 1mL ice-cold PBS buffer.
cells were lysed in 1 ml of 0.1 M NaOH and the intracellular 12'5I_DPIP-LDl
radioactivity was detennined. Protein concentration assay was performed according
to a method described by Bradford (Bradford, 1976). The B..- and ~ for each celt
tine were detennined using commercially obtained software (GraphPad Prism
soflwareoGraphPad Software Inc.). To detennine whether lDl receptors mediated
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the uptake, the same assays were used on cells grown for 4 hours at 37"C, as in the
binding tests, in various ooncentrations of '25I_DPIP-lDl, and in the absence or
presence of 20-fold excess lDl specifIC competitor or AcLDl non-specific
oompetitor.
Results
DPIP was synthesized and labeled with 1251. The maximum fraction of the
input oounts that bound to the cells was about 1f70 for C·33A cells, which have the
highest level of lDL receptor expression. The labeling reaction was completed within
2 hours with little or no substrate decomposition. The radiochemical purity of 1251_
DPIP was found to be greater than 96%, based on the TlC and HPlC results (data
not shown). 125I_DPIP was then inoorporated into lDl by our recently developed and
highly efficient method using seal oil (Xiao et aI., 1999b). Analyzed by column
chromatography, the protein and radioactivity of the resultant product were found to
ovenap (Figure 19), suggesting that a stable 125j_DPIP-lDl conjugate was formed.
The loading efficiency for DPIP was found to be 490:t: 30 moIeculesILDL particle (n
=4), which suggested that potentially as many as about 3,000 radiolabeled iodine
atoms can be loaded into each lDl provided that the labeling efficiency is 100%.
To characterize the integrity of apa B-1 00 and probably the whole lDl particle, 1251.
DPIP-lDl was compared with native lDl using SDS-PAGE. The only stained band
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seen In both lanes was the apa 8-100 band and neither had degradation products
(data not shown).
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Figure 19. Confirmation of 125I_DPIP incorporation into LDL particles. 125j_DPIP_
LDL conjugates were analyzed by gel filtration chromatography through Sephadex
G-25 with PBS. Radioactivity (cpm••) and protein concentration. expressed in
absorbance units. (.t..) were analyzed, as described in the Materials and Methods
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To evaluate in vitro receptor·mediated uptake of ,zsl.DPIP.LDL complex into
cancer celts. we chose three cervical tumor cell lines, HeLa. SiHa. and C·33A. We
first examined the maximum number of LDL receptors using '"'!·LDL The B..... was
detennined at 4°C to assay only binding and avoid the intracellular accumulation of
1~I·LDL, recycling ofLDL receptors orcatabolism of I"'!_LOL Values were corrected
for the non-specific binding of ,Z5I.LOL to the cells when excess unlabeled LOL was
added. HeLa cells were demonstrated to have a B... value of 38,300 ± 9,800
receptors/cell (Figure 20), similar to previous results (Lestavel-Oelattre et at, 1992).
The B
mall values ofSiHa and C-33Awere found to be twice (B...." = 70,3oo:t 6,180;
Figure 21) and thrice (B...... =120,000:t 22,800, Figure 22), respectively, as many as
that of HeLa, indicating that these two cell lines are also good candidates for LDL·
mediated ceU·specific targeting of 125I_DPIP or other hydrophobic compounds using
LDL (Table VII).
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Figure 20. HeLa cell LDL receptor-mediated 125I-LDl binding. Binding assays of
l~-LDL to 3 x 105 to 10B cells with incubation for 4 hours were at 4G(; to avoid
internalization or turnover. The total binding (cpmlmg protein cell extracts) was
determined using no oompetitor (e), the nonspecific binding was determined using
2Q-fold excess unlabeled LDL (-) and then the receptor-mediated binding was
calculated by subtracting the nonspecific from total binding (_). Values are the
mean ± the standard error of the four independent experiments.
-84-
eoooo ,------------------,
1251-lDl (ug proteinlni..)
25
'"
Figure 21. SiHa cell LDL receptor-mediated 12:5I_lDL binding. Conditions and
labels were as for Figure 20.
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Figure 22. e-33A celllDL receptor-mediated 12!11-lDL binding. Conditions and
labels were as for Figure 20.
Table VII. Maximum number of binding sites (B...) and equilibrium dissociation
constant (K.i) for lOl receptor-mediated binding of lOl to cervical
cells
Hela
38.300 ± 9.900
34.0 ± 16.0
SiHa
70,300 t 6,200
23.0 ± 4.4
C-33A
120,400 ± 21.800
49.9 ± 20.2
·8..- ± the standard deviation and K.i ± the standard deviation were determined
from the data of Figures 20-22.
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To assess whether the uptake of 125I-DPIP-LDL was mediated by LDL
receptors in HeLa, SiHa and C-33A cells, competition studies were conducted, as
follows. Uptake of 1251_DPIP_LDL during incubation at 37"C with or without 20-fold
excess native LDL was compared, and the nonspecific competition by LDL was
assessed by the same experiment with or without AcLDL (Figure 23-25). Uptake of
125I_DPIP_LDL was significantly reduced by 20-fold excess native LOL for all three
cell lines (p < 0.01). We confinned the previously reported findings (Goldstein et at,
1979) that 1251_0PIP_LDL uptake was specifIC forthe LDL receptor pathway. We also
found that 125I_DPIP_LDL uptake by HeLa, $iHa and C-33A cells was not competed
(p > 0.05) by AcLOL, which is not recognized by the LDL receptor.
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Figure 23. HeLa cell LDL receptor·mediated 11$1·OPIP-LOL uptake. Cells were
incubated at 3r'C with 12SI_OPIP-LDL complex with no competitor for the LDL
receptor (e), 2D-fold excess native LOL specific competitor ("), or 20·fold excess
AcLOL nonspecific competitor (_). Other oonditions and labels were as for Figure
20. The p values were calculated from the results for all five concentrations in
each curve using the matched pair test for each concentration. ., P < 0.05; +, p >
0.05 for the difference between for each competition curve and the control curve.
Other conditions and labels were as for Figure 20.
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Figure 24. SiHa cell LDL receptor-mediated '2:5I·DPIP_LDL uptake. Conditions,
labels and statistical analysis were as for Figure 23.
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Figure 25. C-33A celllDL receptor-mediated 125I.DPIP.lDL uptake.
Conditions. labels and statistical analysis were as for Figure 23.
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Discussion
Imaging methods are important to clinicians in diagnosis of tumor or
metastasis. Presently used tests have certain limitations and sometimes give false
positive results. Although CT scanning and MRI have had wide application, many
lesions cannot be further characterized with available imaging techniques. Also,
these imaging tests often create new problems that require further investigation.
Clear1y, for oommon cancers. we require new screening tests that are specific but do
not sacrifice sensitivity. Such imaging procedures should still provide diagnosis and
follow-up of small lesions. Ideally, these new imaging methods would scan the whole
body and be sensitive enough to detect lymph node and other metastases (Gucalp
et aI., 1997).
Several carrier systems, such as Iiposomes with or without antibodies. have
been proposed for targeting radiopharmaceuticals to tumors for imaging or therapy
(Carrasquillo. 1993). However. most carTiers have problems. CarTiers such as
nanopartides and liposomes fail to specifically target tumor cells (lasic. 1996;
Emmanual et al.. 1996). Shortcomings of immunocomplexes indude their inability
to target tumor cells in vivo. and the instability of surface antibodies or the antibody-
containing conjugates (Mon and Huang, 1995). LDL is an endogenous lipid carTier
that has also been proposed as a promising vehicle to carry drugs or diagnostic
agents to cancer cells (Jasanada et aI., 1996; Urizzi at al .• 1997). The hydrophobic
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core of LDl reportedly can hold many drug molecules (Vitols et aI., 1990). In
addition, most tumor cells divide rapidly and therefore have increased LDL receptor
levels to supply cholesterol for their high level of membrane synthesis (De Smidt and
van Berkel, 1990(b); Shaw et aI., 1987; Filipowska et aI., 1992). For example,
cervical cancer cells take up SO·fold more lDl than normal gynecologic tissue (Gal
at aI., 1981a). During transport in the blood, lipids within lOL are also protected from
enzymatic degradation, exchange with other lipoproteins, and dissociation from the
complexes.
Todevelop radiopharmaceuticals for in vivo imaging, the high loading potential
of LOL makes incorporating radioactive compounds into LDL an attractive altemative
to labeling LDL directly. The major limitations of directly labeled LDL as a tumor
imaging agent indude inactivation of receptor-binding apo B-100 and low radioactive
specific activity. In this study, radioiodinated DPIP was chosen for loading into LDL
for the following reasons: 1) LDL native structure and function need to remain
biochemically intact. Because DPIP is hydrophobic, it is likely to be stab'e in the
lipophilic LDL core during transport in the blood. It should not disrupt the structure
of the LDL particle and therefore binding of apa B-1 00 to the LDL receptor; 2) the
ethyl group on the l251·DPIP side chain prevents deavage of the ester bond by
lysosomal enzymes. Consequently, the radioactive compound is also stable inside
the cells (Longino et a!., 1983). Further, our recent study of the biodistribution of an
12~.Jabeled radiotracer, which has similar ester structure, in rabbits showed that it
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remained intact (Xlao et al.. 1999); 3) DPIP bears six Iodine atoms on its aromatic
rings for radiolabeling, which would result in high specific radioactivity; and 4)
radioactive iodine isotopes meet the needs of most studies and clinical applications.
1311has been used most often for therapy or imaging (Carrasquillo, 1993). 1251or 1311
can be used for experimental radiotherapy or radioimaging in small mammalian
models, or experimental or applied therapy for humans. In addition, 1231can be used
for imaging for humans.
One potential problem in using LDL as a carrier of drugs or diagnostic agents
is the low incorporation efficiency of the drug molecules. In this study, we
incorporated DPIP into lDL employing our recently developed novel method. We
estimate that approximately 3,000 iodine atoms were incorporated into each lDL
particle, which would provide sufficient radioactivity for most radioimaging
applications, including the imaging of small primary tumors and metastases.
Cervical cancer is the second most common cancer of women in the world
(Par1<in et at, 1999). In this study, we chose three cervical tumor cell lines, Hela,
SiHa, and C-33A, to evaluate in vitro receptor-mediated uptake of l~-DPIP-LDL
complex. Cervical cancer cells have elevated LDL receptors that bind 1&-fold to 30-
fold more LDL than nonnal vital tissues, including the nonmalignant tissues most
highly targeted by LDL. liver and adrenal gland (Gal et aI., 1981b). HeLe is the
cervical tumor cell line used most often for studies of anticancer drug-LDL
complexes. HeLa cells were confirmed to have a high expression of LDL receptor,
which was about 40,000 receptors per cell (Lestavel-Delattre et at, 1992; Figure 20,
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Table VII). In this study, SiHa and C-.33A were found to have higher lDl receptor
expression than Hela. The lDl receptor level wasu~ulated by incubating cells
in medium containing lPOS (Brown and Goldstein, 1976). We demonstrated that
the uptake of '2$l_OPIP.-lDl was competed by native LDL, but not by AcLOL,
suggesting that tumorcells took up '2SI·OPIP.-lOL through the LDL receptor pathway.
Our results also suggested that LDL is a good vehicle to deliver 125I~OPIP to tumor
cells and 12SI_DPIP_lOL may be a promising tumor radioimaging agent. Our
laboratory is further studying in vivo whole body imaging of tumor-bearing small
animals using V-scintigraphy.
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Chapter 5. Conclusion
LDL has been tested as a carrier for anti-cancer drug therapy for about
twenty years. Although drugllDL complexes have shoYm higher selectivity to tumor
cells compared with the free drugs, their targeting effe<:t is not high enough, in terms
of the added toxicity to the anti-cancer drugs, to offset the cost of this delivery
system. Because lowering the toxicity to llOnnal cells, rather than increasing the
toxicity to tumor cells, is the major concern of current cancer chemotherapy, drug·
loaded LDL is thus not a feasible substitute for current formulations.
By contrast to cancer chemotherapy, since most radioimaging agents are
llOn-toxic at their clinical dosage levels, incorporating appropriate radioimaging
agents into LDL may take advantage of the selectivity of LDL to tumor cells without
needing to consider the issue of toxicity to the normal tissues. This makes drug-
loaded LDL a promising alternative to current tumor radioimaging drugs. In Chapter
4 of this thesis, we explored the IXltential of one drugllDL complex as a promising
cervical tumor imaging agent.
Radiolabeled LDL has been studied as an imaging agent for atherosclerosis
for approximately the same length of lime as LDL has been tested as an anti-cancer
drug camero As indicated in Chapter 1, radioactivity on LDL will not stably locale at
the lesion sites because apa B-1 00 protein, through which LDL binds cells, will be
quicklydegraded. Therefore, it is not readily to use LDL for detecting alld monitoring
plaques. In Chapter 2, which is the main part of this thesis, we combined the
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achievements of the studies on using LDL as an anli-cancer drug carrier and using
radiolabeled LOL as an imaging agent for atherosclerosis. and developed three
imaging agents for atherosclerotic lesions by incorporating three non-hydrolyzabfe
compounds into AcLDL. Our results demonstrated that radioimaging agent-loaded
AcLDL has great potential for the purpose of atherosclerosis imaging. On the basis
of the results in this thesis, further studies will be performed using other modified
LOLs, such as OxlDL. methylated LOl, or glucosylated LDl, other radionuclides,
such as Illilm'fc. 1231, or 131 1, and other more potent compounds for both radioimaging
and other imaging uses, including CT and MRI. We believe that clinical applications
of our results will generate some positive outcomes.
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